TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29407718
Drug: Psychoeducation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation plus supportive therapy (PST)
Study: 25451890
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of miglitol and sitagliptin (M+S)
Study: 19841860
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 5 mg infusion
Study: 22061864
Drug: Risedronate (RIS)
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate (RIS) 5 mg oral daily
Study: 17456583
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg
Study: 17456583
Drug: Oseltamivir 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 150 mg
Study: 10866439
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg (in patients treated within 24 h of symptom onset)
Study: 10866439
Drug: Oseltamivir 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 150 mg (in patients treated within 24 h of symptom onset)
Study: 1586708
Drug: Lower-dose methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower-dose methylprednisolone (LDM)
Study: 26152562
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg, then 90 mg BID for 7-9 days)
Study: 26152562
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg, then 75 mg QD for 7-9 days)
Study: 24105694
Drug: PegIFNa2a at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNa2a at 90 μg/week
Study: 24105694
Drug: Imatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib at 400 mg with PegIFNa2a at 90 μg/week
Study: 24105694
Drug: Imatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib at 400 mg with PegIFNa2a at 45 μg/week
Study: 24105694
Drug: Imatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib at 400 mg with PegIFNa2a at 90 μg/week after dose amendment
Study: 24105694
Drug: Imatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib at 400 mg with PegIFNa2a at 45 μg/week after dose amendment
Study: 15015441
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (including antisterone, tetracycline, and metronidazole)
Study: 31435739
Drug: Rocuronium Maruishi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium Maruishi (0.9 mg/kg)
Study: 31435739
Drug: Rocuronium MSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium MSD (0.9 mg/kg)
Study: 19471183
Drug: Yi-Gan San
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yi-Gan San (YGS) at an average daily dosage of 6.7 +/- 2.5 g (range, 2.5-7.5 g)
Study: 20540635
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg/day)
Study: 7851034
Drug: Blood pump
Normalized name: Blood Pump Set 84"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pump flow rate of 200 cc/min
Study: 7851034
Drug: Blood pump
Normalized name: Blood Pump Set 84"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pump flow rate of 500 cc/min
Study: 7851034
Drug: Blood pump
Normalized name: Blood Pump Set 84"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pump flow rates beyond 300 cc/min
Study: 3289598
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg plus nifedipine 20 mg each twice daily
Study: 29947328
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care comprising scar management techniques (massage, moisturiser, silicone treatment, stretching)
Study: 23457535
Drug: Continuous combination
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combination antiretroviral therapy (cART)
Study: 18180976
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg monthly oral ibandronate
Study: 15197428
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg intra-articular ketorolac
Study: 15197428
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc intra-articular bupivacaine 0.25%
Study: 15197428
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intra-articular morphine diluted in 10 cc saline
Study: 15197428
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc saline
Study: 2030189
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus standard inpatient treatment (pharmacotherapy and milieu management)
Study: 29508046
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training associated with behavioral therapy (GPFMT)
Study: 21912128
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly supervised brushing with a self-applied gel containing 12,500 ppm fluoride
Study: 21912128
Drug: Weekly supervised
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supervised use of the gel
Study: 16681480
Drug: Testosterone propionate
Normalized name: Testosterone Propionate
DrugBank: Testosterone propionate (DB01420)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone propionate (2 mg)
Study: 11406907
Drug: Low-dose perindopril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose perindopril 2 mg plus indapamide 0.625 mg (P/I)
Study: 11406907
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg (L50)
Study: 9728841
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution (saline)
Study: 7876403
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (40 mg, 100 mg, 250 mg, 500 mg)
Study: 7876403
Drug: Methylprednisolone suleptanate
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone suleptanate (40 mg, 100 mg, 250 mg, 500 mg)
Study: 3555030
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg twice daily)
Study: 30924702
Drug: SPN-812 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 200 mg/day
Study: 30358731
Drug: Intravaginal 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 0.50% DHEA (6.5 mg)
Study: 24872223
Drug: Other variables
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other variables measured (urine N-telopeptide of type I collagen/creatinine ratio, Tanner score, serum parathyroid hormone, 25-hydroxyvitamin D, weight, height, body mass index)
Study: 12809074
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU; 120 mg daily, for 3 months)
Study: 27235849
Drug: Ibuprofen (1200mg/d)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (1200mg/d)
Study: 20182022
Drug: Antihypertensive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatments (specific subclasses: calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin-AT1-receptor-blockers)
Study: 20182022
Drug: Antihypertensive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatments (placebo-controlled)
Study: 16096124
Drug: Preferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred treatment
Study: 10071003
Drug: exercise therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: exercise therapies
Study: 7493304
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients who completed rIFN‐alpha 2b treatment
Study: 7493304
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients post-therapy
Study: 1973094
Drug: Combination low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination low sodium, low fat, high fibre diet
Study: 25581612
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy or tumor necrosis factor plus methotrexate treatment
Study: 2668757
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppositories
Study: 3698595
Drug: Meteneprost 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meteneprost 10 mg vaginal suppositories
Study: 17919762
Drug: Twice-daily injections
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily injections of biphasic insulin aspart 30
Study: 17919762
Drug: Three-times-daily injections
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-times-daily injections of insulin aspart with or without NPH insulin (multiple daily injections)
Study: 1958445
Drug: Tenoxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (40 mg daily for 2 days, then 20 mg daily for 8 days)
Study: 31868632
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of R-CHOP plus two doses of rituximab
Study: 25970667
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity intervention lasting 30 min over one academic year, led by preschool teachers with educational components for parents and teachers.
Study: 15792142
Drug: Pronoran (piribedil)
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pronoran (piribedil) 50 mg per day for 30 days
Study: 15792142
Drug: Pronoran (piribedil)
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pronoran (piribedil) 50 mg per day for 90 days
Study: 7589011
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg day‐1)
Study: 1771612
Drug: Concentrated ethylester
Normalized name: Ethylester kyseliny karbaminove
DrugBank: Urethane (DB04827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated ethylester compound of n‐3 fatty acids (3.15 g EPA and 1.89 g DHA daily)
Study: 1771612
Drug: Concentrated ethylester
Normalized name: Ethylester kyseliny karbaminove
DrugBank: Urethane (DB04827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated ethylester compound of n‐3 fatty acids
Study: 1771612
Drug: Concentrated ethylester
Normalized name: Ethylester kyseliny karbaminove
DrugBank: Urethane (DB04827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated ethylester compound of n‐3 fatty acids and Corn oil (control)
Study: 6751736
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine hydrochloride (50 mg three times daily)
Study: 26544055
Drug: Alternative hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative hydration system (2 glucose/electrolyte solutions - 'two bag system')
Study: 26544055
Drug: Traditional hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional hydration system (1 glucose/electrolyte solution)
Study: 7805982
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of color Doppler and CA 125 or morphological assessments
Study: 12063985
Drug: Interferon-alpha-2b plus
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha-2b plus placebo for 24 weeks followed by 24 weeks of combined therapy
Study: 2672898
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% bupivacaine with epinephrine, 5 micrograms/ml
Study: 2672898
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml preservative-free saline
Study: 786663
Drug: Prorenoate potassium
Normalized name: Propanoic acid
DrugBank: Propanoic acid (DB03766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prorenoate potassium 45 mg
Study: 7066166
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg
Study: 18544992
Drug: Taxotere plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxotere plus prednisolone (30 mg/m2 weekly during 5 of 6 weeks + prednisolone 5 mg orally twice daily)
Study: 18544992
Drug: Prednisolone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (5 mg orally twice daily)
Study: 15975314
Drug: ABCBS herbs
Normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABCBS herbs orally taken in addition to conventional treatment
Study: 15975314
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with western medicine (WM) and Salvia injection
Study: 8591941
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg single dose
Study: 25866384
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 10 sessions before surgery
Study: 17416113
Drug: Diamicron 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamicron 80 mg tablet from Servier (Ireland) Industries Limited (Control)
Study: 9661037
Drug: Itraconazole solution
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole solution (200 mg)
Study: 9661037
Drug: Hydroxyitraconazole solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyitraconazole solution (200 mg)
Study: 9661037
Drug: Capsule formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulations (200 mg)
Study: 1489075
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia induced with thiopentone 2‐5 mg/kg, continued with low‐dose fentanyl (1‐2 micrograms/kg), oxygen/nitrous oxide/isoflurane (30/70/0.1‐0.5%), vecuronium
Study: 2860271
Drug: Intrapleural Corynebacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural Corynebacterium parvum 7 mg
Study: 29526416
Drug: CMR-LGE quantification
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMR-LGE quantification using a threshold of 8SD for peak TnI>50ng/mL
Study: 29526416
Drug: CMR-LGE quantification
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMR-LGE quantification using a threshold of 4SD for peak TnI>95ng/mL
Study: 24739799
Drug: Doxazosin 2
Normalized name: doxazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 2 mg twice daily
Study: 7822649
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection system for delivering local anesthetic
Study: 30763142
Drug: Darolutamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darolutamide (600 mg [two 300-mg tablets] twice daily)
Study: 26795844
Drug: 20 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg/kg palonosetron
Study: 28941006
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 150 μg/kg ondansetron
Study: 23017464
Drug: Savoury food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savoury food items (e.g., mashed potatoes, tortilla chips)
Study: 23017464
Drug: Savoury food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savoury food items (e.g., canned tomatoes, tortilla chips)
Study: 21871095
Drug: Robotic arm
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic arm therapy
Study: 9124993
Drug: Piperacillin/tazobactam (P/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (P/T) monotherapy, daily dose of 12/1.5 g for an average of 10 days
Study: 8354894
Drug: Interleukin-1 alpha
Normalized name: interleukin-1 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-1 alpha (IL-1 alpha) infusion
Study: 3730024
Drug: Intravenous ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ifosfamide (Holoxan) at 1 g/m2
Study: 25992488
Drug: Indapamide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (1 mg/day)
Study: 23084000
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with DCAD of 50 mEq/kg DM + 25(OH)D (3 mg/steer per day)
Study: 23084000
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with DCAD of 150 mEq/kg DM + 25(OH)D (3 mg/steer per day)
Study: 15515745
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone (thyroxine) replacement
Study: 31926085
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment in children
Study: 14734877
Drug: G‐ORS
Normalized name: Oral Rehydration Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐ORS
Study: 28192629
Drug: Co-trimoxazole (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (960 mg twice daily)
Study: 15232813
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve block plus IV PCA morphine (G1)
Study: 15232813
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine and fentanyl PCA infusion (G2)
Study: 8996133
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg twice daily) in patients who vomited in the first 24 hours
Study: 8996133
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg every 6 hours) in patients who vomited in the first 24 hours
Study: 27522871
Drug: Self-reported drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported drug use (TLFB)
Study: 24399455
Drug: Magnetic field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic field therapy (2 Hz) applied to each hip region for 20 min, n = 35
Study: 24399455
Drug: Placebo magnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo magnetic field therapy applied to each hip region for 20 min, n = 31
Study: 24074502
Drug: Dexamethasone 30
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 30 mg perioperatively
Study: 18853973
Drug: Adalimumab maintenance
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab maintenance therapy (40 mg every other week)
Study: 18853973
Drug: Adalimumab maintenance
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab maintenance therapy (40 mg weekly)
Study: 18853973
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after induction therapy
Study: 15994121
Drug: Partial sleep
Normalized name: SOY OIL,PARTIALLY HYDROGENATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial sleep deprivation therapy combined with sertraline (LPSD group)
Study: 15994121
Drug: Sertraline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline monotherapy (Control group)
Study: 12448241
Drug: Amoxicillin/clavulanate single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate single-dose regimen
Study: 2794058
Drug: MK-329 10
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-329 10 mg
Study: 14982
Drug: Flunisolide (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide (active drug)
Study: 14522725
Drug: High physical
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High physical activity (HPA) treatment with an energy expenditure (EE) goal of 2500 kcal/wk
Study: 14522725
Drug: Standard behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavior therapy (SBT) for obesity with an EE goal of 1000 kcal/wk
Study: 31601587
Drug: Multicomponent self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent self-management intervention for opioid tapering
Study: 26942358
Drug: Quickstart group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quickstart group (etonogestrel implants with mifepristone)
Study: 26942358
Drug: Afterstart group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afterstart group (etonogestrel implants after abortion)
Study: 25122041
Drug: tizanidine 4
Normalized name: tizanidine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tizanidine 4 mg
Study: 22997780
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (Sodium Nitroprusside, Mannite, etc.)
Study: 24796048
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group
Study: 17483139
Drug: Weekly support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly support
Study: 16350718
Drug: Soluble VEGF
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Soluble VEGF receptor concentrations in patients with benign and malignant thyroid tumors